Thrive Earlier Detection Stock

Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care.

Sign up today and learn more about Thrive Earlier Detection Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Thrive Earlier Detection Stock

Thrive Earlier Detection Corp. is a healthcare company focused on incorporating earlier cancer detection into routine medical care to extend and save lives. Thrive is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences and Gamma3.

Funding History

May 2019$110M
July 2020$257M


Chief Commercial Officer

Matt Franklin


Kenneth Kinzler


David J. Daly


Nickolas Papadopoulos

Chief People Officer

Semi Trotto

Chief Financial Officer

Isaac Ro


Bert Vogelstein

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: